Sarah B. Noonberg, M.D., Ph.D., Chief Medical Officer
Sarah B. Noonberg, M.D., Ph.D., currently serves as the Chief Medical Officer of Metagenomi. She has over 20 years of industry experience leading development programs from discovery to commercialization across a range of indications. Prior to Metagenomi, Dr. Noonberg served as the Chief Medical Officer for several companies, including Maze Therapeutics, Nohla Therapeutics, and Prothena, and as Group Vice President and Head of Global Clinical Development at BioMarin Pharmaceuticals. She also previously held several positions at Medivation, including as Senior Vice President of Early Development. Dr. Noonberg serves on the Board of Directors of Marinus Pharmaceuticals and previously served on the Board of Directors of Protagonist Therapeutics and Neoleukin Therapeutics. She received her M.D. from the University of California, San Francisco, her Ph.D. in Bioengineering from the University of California, Berkeley, and her B.S. in Engineering from Dartmouth College. She is a board-certified internist and completed her residency at Johns Hopkins Hospital.